DocMorris AG

Daniel Wüest becomes new CFO at DocMorris - Seite 2

 

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: [e-mail], phone: [phone]

Media contact
Torben Bonnke, Director Communications
Email: [e-mail], phone: [phone]

Agenda

20 August 2024	2024 Half-year results (conference call/webcast)
15 October 2024	Q3/2024 Trading update

 

DocMorris
The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. The company was renamed from Zur Rose Group AG to DocMorris AG in May 2023 after the Swiss business was sold to Migros/Medbase. Excluding the Swiss business, about 1,600 employees in Germany, the Netherlands, Spain, France and Switzerland generated an external revenue of CHF 1,038 million serving over 9 million active customers in 2023. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

 

---

End of Inside Information

---

Language:	English
Company:	DocMorris AG
	Walzmühlestrasse 49
	8500 Frauenfeld
	Switzerland
ISIN:	CH0042615283
Listed:	SIX Swiss Exchange
EQS News ID:	1897901

End of Announcement	EQS News Service

1897901  08-May-2024 CET/CEST